Compare General Mills, Inc. (GIS) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Mills, Inc. vs Novo Nordisk A/S — how do they compare? General Mills, Inc. trades at $38.14 (market cap $20.24B), while Novo Nordisk A/S trades at $46.2 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 10.3× General Mills, Inc.'s market cap, and General Mills, Inc. pays the higher dividend (6.43%). Which is the better fit depends on your goals.
| GIS | NVO | |
|---|---|---|
Market Cap | $20.24B | $207.85B |
Sector | Consumer Staples | Health |
52-Week High | $51.11 | $63.98 |
52-Week Low | $32.17 | $35.29 |
Enterprise Value | $33.73B | $222.55B |
Dividend Yield | 6.43% | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Mills (GIS) trades at $37.97, up 1.89% today, showing a mixed technical picture with a bullish moving average signal but a neutral RSI. Fundamentally, the company reported a net loss in 2026, compressing margins, though it beat Q2 2026 EPS estimates. Recent news highlights strategic partnerships in regenerative agriculture and new product launches to drive growth amid challenging consumer demand.
The outlook is cautious; while the stock appears undervalued on a P/E basis and offers a dividend, significant risks include persistent margin pressure, high debt levels, and weak sales growth. Analyst consensus is predominantly Hold, reflecting uncertainty about the company's turnaround efforts in a competitive market.
Novo Nordisk (NVO) trades at $46.28, down 3.05% today, with technical indicators showing neutral signals. The company maintains strong fundamentals with Q2 2026 EPS beating expectations at $0.96 versus $0.77 estimate, continuing a pattern of earnings outperformance. Revenue growth remains solid with 2025 revenue reaching $309.1B and net income margin of 33.14%. Analyst sentiment remains positive with 57.9% recommending Buy, though recent news highlights competitive pressures from Eli Lilly in the GLP-1 market.
NVO presents a compelling investment case with robust profitability metrics including 59.82% ROE and attractive valuation at 11.62 P/E. However, increasing competition in weight-loss drugs and pricing pressures create headwinds. The stock's current technical neutrality suggests potential consolidation near current levels, with fundamental strength supporting long-term growth prospects despite near-term competitive challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About General Mills, Inc.
General Mills is a leading global packaged food company that produces snacks, cereal, convenient meals, yogurt, dough, baking mixes and ingredients, pet food, and superpremium ice cream. Its largest brands are Nature Valley, Cheerios, Old El Paso, Yoplait, Pillsbury, Betty Crocker, BLUE, and Haagen-Dazs. In fiscal 2022, 77% of its revenue was derived from the United States, although the company also operates in Canada, Europe, Australia, Asia, and Latin America. While most of General Mills' products are sold through retail stores to consumers, the company also sells products into the food-service channel and the commercial baking industry.
Read more on GIS →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
